Bile Acid Binding Resin Improves Metabolic Control through the Induction of Energy Expenditure

Background Besides well-established roles of bile acids (BA) in dietary lipid absorption and cholesterol homeostasis, it has recently become clear that BA is also a biological signaling molecule. We have shown that strategies aimed at activating TGR5 by increasing the BA pool size with BA administration may constitute a significant therapeutic advance to combat the metabolic syndrome and suggest that such strategies are worth testing in a clinical setting. Bile acid binding resin (BABR) is known not only to reduce serum cholesterol levels but also to improve glucose tolerance and insulin resistance in animal models and humans. However, the mechanisms by which BABR affects glucose homeostasis have not been established. We investigated how BABR affects glycemic control in diet-induced obesity models. Methods and Findings We evaluated the metabolic effect of BABR by administrating colestimide to animal models for the metabolic syndrome. Administration of BABR increased energy expenditure, translating into significant weight reduction and insulin sensitization. The metabolic effects of BABR coincide with activation of cholesterol and BA synthesis in liver and thermogenesis in brown adipose tissue. Interestingly, these effects of BABR occur despite normal food intake and triglyceride absorption. Administration of BABR and BA had similar effects on BA composition and thermogenesis, suggesting that they both are mediated via TGR5 activation. Conclusion Our data hence suggest that BABR could be useful for the management of the impaired glucose tolerance of the metabolic syndrome, since they not only lower cholesterol levels, but also reduce obesity and improve insulin resistance.

[1]  H. Nakano,et al.  Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. , 2012, Journal of diabetes and its complications.

[2]  M. Orešič,et al.  Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.

[3]  J. Auwerx,et al.  Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure* , 2011, The Journal of Biological Chemistry.

[4]  F. Kuipers,et al.  Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism , 2010, Hepatology.

[5]  M. Manns,et al.  Plasma bile acids are not associated with energy metabolism in humans , 2010, Nutrition & metabolism.

[6]  F. Gonzalez,et al.  Intestinal FXR-mediated FGF15 production contributes to diurnal control of hepatic bile acid synthesis in mice , 2010, Laboratory Investigation.

[7]  M. Ruth Cold-Activated Brown Adipose Tissue in Healthy Men , 2010 .

[8]  J. Orava,et al.  Functional brown adipose tissue in healthy adults. , 2009, The New England journal of medicine.

[9]  J. Auwerx,et al.  TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.

[10]  E. Palmer,et al.  Identification and importance of brown adipose tissue in adult humans. , 2009, The New England journal of medicine.

[11]  R. Goldberg,et al.  Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. , 2008, Archives of internal medicine.

[12]  J. Rosenstock,et al.  Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.

[13]  R. Goldberg,et al.  Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. , 2008, Archives of internal medicine.

[14]  J. Auwerx,et al.  Compromised Intestinal Lipid Absorption in Mice with a Liver-Specific Deficiency of Liver Receptor Homolog 1 , 2007, Molecular and Cellular Biology.

[15]  T. Ogihara,et al.  Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin , 2007, Diabetes.

[16]  S. Schwartz,et al.  Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. , 2007, Clinical therapeutics.

[17]  J. Auwerx,et al.  Endocrine functions of bile acids , 2006, The EMBO journal.

[18]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[19]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[20]  G. Tsujimoto,et al.  Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.

[21]  Sander M Houten,et al.  Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. , 2004, The Journal of clinical investigation.

[22]  J. Auwerx,et al.  The enterohepatic nuclear receptors are major regulators of the enterohepatic circulation of bile salts , 2004, Annals of medicine.

[23]  D. Russell The enzymes, regulation, and genetics of bile acid synthesis. , 2003, Annual review of biochemistry.

[24]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[25]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[26]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[27]  J. Auwerx,et al.  SRC-1 and TIF2 Control Energy Balance between White and Brown Adipose Tissues , 2002, Cell.

[28]  Takao Nakamura,et al.  Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.

[29]  J. Auwerx,et al.  The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. , 2002, Molecular endocrinology.

[30]  D. Russell,et al.  Loss of nuclear receptor SHP impairs but does not eliminate negative feedback regulation of bile acid synthesis. , 2002, Developmental cell.

[31]  M. Karin,et al.  Redundant pathways for negative feedback regulation of bile acid production. , 2002, Developmental cell.

[32]  D. French,et al.  Printed in U.S.A. Copyright © 2002 by The Endocrine Society Transgenic Mice Expressing Human Fibroblast Growth Factor-19 Display Increased Metabolic Rate and Decreased Adiposity , 2022 .

[33]  P. Larsen,et al.  Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. , 2002, Endocrine reviews.

[34]  Masahiro Tohkin,et al.  Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.

[35]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[36]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[37]  M. Makishima,et al.  Identification of a nuclear receptor for bile acids. , 1999, Science.

[38]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[39]  Jasmine Chen,et al.  Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.

[40]  H. Yamaguchi,et al.  Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia. , 1997, Atherosclerosis.

[41]  S. Grundy,et al.  Cholestyramine Therapy for Dyslipidemia in NonInsulin-dependent Diabetes Mellitus: A Short-Term, Double-Blind, Crossover Trial , 1994, Annals of Internal Medicine.

[42]  M. Maeda,et al.  Simultaneous determination of bile acids in rat bile and serum by high-performance liquid chromatography. , 1993, Journal of chromatography.

[43]  G. Bray,et al.  Effects of cholecystokinin on sympathetic activity to interscapular brown adipose tissue , 1992, Brain Research.

[44]  G. Greeley,et al.  Chronic Effect of Oral Cholestyramine, a Bile Salt Sequestrant, and Exogenous Cholecystokinin on Insulin Release in Rats , 1992, Pancreas.

[45]  T. Nagasaka,et al.  Changes in brown adipose tissue metabolism following intraventricular vasoactive intestinal peptide and other gastrointestinal peptides in rats. , 1989, The Japanese Journal of Physiology.

[46]  A. Fellgiebel,et al.  Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion , 1988, European journal of clinical investigation.

[47]  J. Garbutt,et al.  Effect of cholestyramine on bile acid metabolism in normal man. , 1972, The Journal of clinical investigation.

[48]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.